Anika Therapeutics, Inc. (ANIK) Stock
ANIK Key Statistics
About Anika Therapeutics, Inc.
Anika Therapeutics, Inc. is a company dedicated to joint preservation, innovating and providing early intervention orthopedic care across the globe, including the United States and Europe. Their core focus areas include osteoarthritis (OA) pain management, regenerative solutions, soft tissue repair, and advanced bone-preserving joint technologies. All of Anika's products are developed, manufactured, and commercialized utilizing their proprietary hyaluronic acid (HA) technology platform. Their comprehensive product lines feature an OA pain management family, which includes established treatments like Monovisc, Orthovisc, Cingal, and Hyvisc, all designed to alleviate discomfort from osteoarthritis. The company's joint preservation and restoration offerings are extensive, comprising approximately 150 bone-sparing joint technology products, alongside solutions for sports medicine soft tissue repair and orthopedic regenerative therapies. Furthermore, Anika leverages its HA expertise in a non-orthopedic product family, developing applications such as adhesion barriers, advanced wound care products, ophthalmic solutions, and ear, nose, and throat treatments. Anika Therapeutics, Inc. was established in 1983 and is based in Bedford, Massachusetts.
CEO: Stephen D. Griffin. Company website
ANIK — Frequently Asked Questions
What is the ANIK stock price today?
Anika Therapeutics, Inc. (ANIK) trades at $20.81, down 1.05% on the day, as of Sep 20, 2026 15:01 UTC.
What is Anika Therapeutics, Inc.'s market cap?
Anika Therapeutics, Inc. has a market capitalisation of $278.50M, calculated from the live ANIK share price and shares outstanding.
What is the P/E ratio of ANIK?
ANIK has no meaningful price-to-earnings ratio: Anika Therapeutics, Inc. lost $0.27 per share over the last twelve months, and a P/E is only defined on positive earnings.
How much revenue does Anika Therapeutics, Inc. make?
Anika Therapeutics, Inc. generated revenue of $120.65M over the trailing twelve months, which puts the stock at 2.31 times sales.
What is the 52-week range for ANIK?
ANIK has traded between $8.56 and $22.88 over the past 52 weeks, and the last price is 9.0% below that high.
Is Anika Therapeutics, Inc. profitable?
No. Anika Therapeutics, Inc. is loss-making, with a net margin of -3.14% over the trailing twelve months.
What is the analyst price target for ANIK?
Wall Street analysts rate ANIK Buy, with an average price target of $21.00, 0.9% above the current price.
What sector is Anika Therapeutics, Inc. in?
Anika Therapeutics, Inc. is classified under the Healthcare sector and the Medical - Specialties industry, and is domiciled in US.
Who is the CEO of Anika Therapeutics, Inc.?
Stephen D. Griffin is the chief executive of Anika Therapeutics, Inc., which employs 235 people.
Where can I track ANIK in real time?
QFI Terminal shows ANIK with live charts, full financials, the options chain with gamma exposure, institutional ownership and analyst ratings on one screen. The free plan has no time limit and asks for no card.
See ANIK live in QFI Terminal
Interactive charts, full financials, options chain, gamma exposure, ownership and analyst ratings, all in one institutional-grade terminal.
Open ANIK in Terminal See plans